Fusion Pharmaceuticals has acquired Ipsen's development and assets related to IPN-1087, a small molecule that targets the NTSR1 receptor, a protein expressed in several types of solid tumors. Fusion intends to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors. As payment, Fusion has issued 600,000 shares of common stock to Ipsen. The agreement also provides for payments after certain development milestones are reached.